ubmslateRN-logo-ubm

RN Mobile Menu

Search form

Topics:

Q&As

Q&As

(©ksenvitaln/Shutterstock.com)

Q&A: Two experts discuss proposals for formal CVD risk calculators in RA and the need for long-term research to validate them.

Barbara Vilen, Ph.D.

In this Q&A, Rheumatology Network speaks with Dr. Barbara Vilen who is making strides in both basic and translational research that may lead to new therapeutic targets for lupus.

Stephen Katz M.D., Ph.D.

In this Q&A, Rheumatology Network speaks with Dr. Stephen Katz about the NIAMS Action Plan for Lupus Research.

Timothy B. Niewold, M.D

With the hope of wasting less time on medications doomed to fail, researchers are seeking biomarkers to predict a patient’s response to particular RA treatments.

Prem N. Ramkumar, M.D.

Prem N. Ramkumar, M.D., the author of a recent analysis on readmission rates in TJA, speaks with Rheumatology Network about why readmission rates matter.

 Michelle Petri, M.D.

Adherence to lupus treatment can be less than ideal, says Dr. Michelle Petri of Johns Hopkins. This is why monitoring whole-blood hydroxychloroquine levels is an important part of treatment.

Yehuda Shoenfeld, M.D.

In patients with CNS lupus, early evidence shows the presence of the development of dementia, says Dr. Yehuda Shoenfeld of Israel. "Lupus is a disease of young females, so it's not elderly females with dementia at this age."

Pages

Subscribe to Q&As on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.